Traverse 2024 Study. Named the traverse study, results of the trial, which compared risk of cardiovascular events in people with hypogonadism using testosterone therapy versus placebo, indicate use of testosterone therapy was noninferior. Participants included men aged 45 to 80 years with hypogonadism and prediabetes or diabetes who were enrolled in traverse between may 23, 2018, and february 1, 2022.
The results, from the phase 4 traverse study, showed a negligible difference in cv events among men aged 45 to 80 years with hypogonadism who were treated with testosterone (7%) and those treated. Participants included men aged 45 to 80 years with hypogonadism and prediabetes or diabetes who were enrolled in traverse between may 23, 2018, and february 1, 2022.
